These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 38579682)

  • 1. A simultaneous knockout knockin genome editing strategy in HSPCs potently inhibits CCR5- and CXCR4-tropic HIV-1 infection.
    Dudek AM; Feist WN; Sasu EJ; Luna SE; Ben-Efraim K; Bak RO; Cepika AM; Porteus MH
    Cell Stem Cell; 2024 Apr; 31(4):499-518.e6. PubMed ID: 38579682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disruption of HIV-1 co-receptors CCR5 and CXCR4 in primary human T cells and hematopoietic stem and progenitor cells using base editing.
    Knipping F; Newby GA; Eide CR; McElroy AN; Nielsen SC; Smith K; Fang Y; Cornu TI; Costa C; Gutierrez-Guerrero A; Bingea SP; Feser CJ; Steinbeck B; Hippen KL; Blazar BR; McCaffrey A; Mussolino C; Verhoeyen E; Tolar J; Liu DR; Osborn MJ
    Mol Ther; 2022 Jan; 30(1):130-144. PubMed ID: 34737067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous Knockout of CXCR4 and CCR5 Genes in CD4+ T Cells via CRISPR/Cas9 Confers Resistance to Both X4- and R5-Tropic Human Immunodeficiency Virus Type 1 Infection.
    Yu S; Yao Y; Xiao H; Li J; Liu Q; Yang Y; Adah D; Lu J; Zhao S; Qin L; Chen X
    Hum Gene Ther; 2018 Jan; 29(1):51-67. PubMed ID: 28599597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR/Cas9 genome editing of CCR5 combined with C46 HIV-1 fusion inhibitor for cellular resistant to R5 and X4 tropic HIV-1.
    Khamaikawin W; Saisawang C; Tassaneetrithep B; Bhukhai K; Phanthong P; Borwornpinyo S; Phuphuakrat A; Pasomsub E; Chaisavaneeyakorn S; Anurathapan U; Apiwattanakul N; Hongeng S
    Sci Rep; 2024 May; 14(1):10852. PubMed ID: 38741006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4 is expressed on a heterogeneous subset of hematopoietic progenitors, which persistently harbor CXCR4 and CCR5-tropic HIV proviral genomes in vivo.
    Sebastian NT; Zaikos TD; Terry V; Taschuk F; McNamara LA; Onafuwa-Nuga A; Yucha R; Signer RAJ; Riddell J; Bixby D; Markowitz N; Morrison SJ; Collins KL
    PLoS Pathog; 2017 Jul; 13(7):e1006509. PubMed ID: 28732051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetically-edited induced pluripotent stem cells derived from HIV-1-infected patients on therapy can give rise to immune cells resistant to HIV-1 infection.
    Teque F; Ye L; Xie F; Wang J; Morvan MG; Kan YW; Levy JA
    AIDS; 2020 Jul; 34(8):1141-1149. PubMed ID: 32287059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineering HIV-1-resistant T-cells from short-hairpin RNA-expressing hematopoietic stem/progenitor cells in humanized BLT mice.
    Ringpis GE; Shimizu S; Arokium H; Camba-Colón J; Carroll MV; Cortado R; Xie Y; Kim PY; Sahakyan A; Lowe EL; Narukawa M; Kandarian FN; Burke BP; Symonds GP; An DS; Chen IS; Kamata M
    PLoS One; 2012; 7(12):e53492. PubMed ID: 23300932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases.
    Wilen CB; Wang J; Tilton JC; Miller JC; Kim KA; Rebar EJ; Sherrill-Mix SA; Patro SC; Secreto AJ; Jordan AP; Lee G; Kahn J; Aye PP; Bunnell BA; Lackner AA; Hoxie JA; Danet-Desnoyers GA; Bushman FD; Riley JL; Gregory PD; June CH; Holmes MC; Doms RW
    PLoS Pathog; 2011 Apr; 7(4):e1002020. PubMed ID: 21533216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR/Cas9-Mediated CCR5 Ablation in Human Hematopoietic Stem/Progenitor Cells Confers HIV-1 Resistance In Vivo.
    Xu L; Yang H; Gao Y; Chen Z; Xie L; Liu Y; Liu Y; Wang X; Li H; Lai W; He Y; Yao A; Ma L; Shao Y; Zhang B; Wang C; Chen H; Deng H
    Mol Ther; 2017 Aug; 25(8):1782-1789. PubMed ID: 28527722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic haute couture to block HIV-1 at front doors.
    Ancuta P
    Cell Stem Cell; 2024 Apr; 31(4):433-434. PubMed ID: 38579679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation.
    Gupta RK; Abdul-Jawad S; McCoy LE; Mok HP; Peppa D; Salgado M; Martinez-Picado J; Nijhuis M; Wensing AMJ; Lee H; Grant P; Nastouli E; Lambert J; Pace M; Salasc F; Monit C; Innes AJ; Muir L; Waters L; Frater J; Lever AML; Edwards SG; Gabriel IH; Olavarria E
    Nature; 2019 Apr; 568(7751):244-248. PubMed ID: 30836379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CCR5 editing by Staphylococcus aureus Cas9 in human primary CD4
    Xiao Q; Chen S; Wang Q; Liu Z; Liu S; Deng H; Hou W; Wu D; Xiong Y; Li J; Guo D
    Retrovirology; 2019 Jun; 16(1):15. PubMed ID: 31186067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CCR5 Gene Edited CD34
    Karuppusamy KV; Demosthenes JP; Venkatesan V; Christopher AC; Babu P; Azhagiri MK; Jacob A; Ramalingam VV; Rangaraj S; Murugesan MK; Marepally SK; Varghese GM; Srivastava A; Kannangai R; Thangavel S
    Front Immunol; 2022; 13():792684. PubMed ID: 35359982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CXCR4 and CCR5 shRNA transgenic CD34+ cell derived macrophages are functionally normal and resist HIV-1 infection.
    Anderson J; Akkina R
    Retrovirology; 2005 Aug; 2():53. PubMed ID: 16109172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lineage-specific expression of human immunodeficiency virus (HIV) receptor/coreceptors in differentiating hematopoietic precursors: correlation with susceptibility to T- and M-tropic HIV and chemokine-mediated HIV resistance.
    Chelucci C; Casella I; Federico M; Testa U; Macioce G; Pelosi E; Guerriero R; Mariani G; Giampaolo A; Hassan HJ; Peschle C
    Blood; 1999 Sep; 94(5):1590-600. PubMed ID: 10477684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Killing two birds with one stone: CRISPR/Cas9 CCR5 knockout hematopoietic stem cells transplantation to treat patients with HIV infection and hematological malignancies concurrently.
    Au TY; Arudkumar J; Assavarittirong C; Benjamin S
    Clin Exp Med; 2023 Dec; 23(8):4163-4175. PubMed ID: 37500934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome editing of the HIV co-receptors CCR5 and CXCR4 by CRISPR-Cas9 protects CD4
    Liu Z; Chen S; Jin X; Wang Q; Yang K; Li C; Xiao Q; Hou P; Liu S; Wu S; Hou W; Xiong Y; Kong C; Zhao X; Wu L; Li C; Sun G; Guo D
    Cell Biosci; 2017; 7():47. PubMed ID: 28904745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Strategies and Challenges of CCR5 Gene Editing in Hematopoietic Stem and Progenitor Cells for the Treatment of HIV.
    Karuppusamy KV; Babu P; Thangavel S
    Stem Cell Rev Rep; 2021 Oct; 17(5):1607-1618. PubMed ID: 33788143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Evaluation of a Novel TALEN Targeting CCR5 Confirms Efficacy and Safety in Conferring Resistance to HIV-1 Infection.
    Romito M; Juillerat A; Kok YL; Hildenbeutel M; Rhiel M; Andrieux G; Geiger J; Rudolph C; Mussolino C; Duclert A; Metzner KJ; Duchateau P; Cathomen T; Cornu TI
    Biotechnol J; 2021 Jan; 16(1):e2000023. PubMed ID: 33103367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome modification of CXCR4 by Staphylococcus aureus Cas9 renders cells resistance to HIV-1 infection.
    Wang Q; Chen S; Xiao Q; Liu Z; Liu S; Hou P; Zhou L; Hou W; Ho W; Li C; Wu L; Guo D
    Retrovirology; 2017 Nov; 14(1):51. PubMed ID: 29141633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.